1 to 10 of 2,175 literature results

• Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

  BACKGROUND: Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose high costs on health-care systems. Our aim was to assess the effect of fenofibrate…

  Authors: Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech, FIELD study investigators

  Source: Lancet 2009 May 23

  View Full Text

• Pleiotropic effects of fenofibrate.

  Fenofibrate represents the most commonly used fibric acid derivative. The drug exerts its metabolic effects by modulating the expression of several genes involved in lipoprotein metabolism. In additio…

  Authors: V Tsimihodimos, E Liberopoulos, M Elisaf

  Source: Current pharmaceutical design 2009

  View Full Text

• Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

  BACKGROUND: Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with …

  Authors: A C Keech, P Mitchell, P A Summanen, J O'Day, T M E Davis, M S Moffitt, M-R Taskinen, R J Simes, D Tse, E Williamson,…

  Source: Lancet 2007 Nov 17

  View Full Text

• Fenofibrate and risk of minor amputations in diabetes.

  Authors: Sergio Fazio, MacRae F Linton

  Source: Lancet 2009 May 23

  View Full Text

• Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: FIELD Helsinki Substudy.

  Objective. Although fenofibrate was associated with less progression of albuminuria in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, it is unknown if it has any effect on …

  Authors: Carol Forsblom, Anne Hiukka, Eeva S Leinonen, Jouko Sundvall, Per-Henrik Groop, Marja-Riitta Taskinen

  Source: Diabetes care 2009 Oct 21

  View Full Text

• Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  OBJECTIVE: We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic …

  Authors: Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael D'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

  Source: Diabetes care 2009 Mar

  View Full Text

• Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  Aims To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate In…

  Authors: David C Burgess, David Hunt, Liping Li, Diana Zannino, Elizabeth Williamson, Timothy M E Davis, Markku Laakso, Y Antero Kesäniemi, Jun Zhang, Raymond W Sy,…

  Source: European heart journal 2009 Sep 29

  View Full Text

• Fenofibrate and diabetic retinopathy.

  Authors: Ning Cheung, T Y Wong

  Source: Lancet 2008 Mar 1

  View Full Text

• Fenofibrate and diabetic retinopathy.

  Authors: Gerald Liew, Mark Gillies, Jie Jin Wang

  Source: Lancet 2008 Mar 1

  View Full Text

• Fenofibrate and diabetic retinopathy.

  Authors: John Firth

  Source: Lancet 2008 Mar 1

  View Full Text